CalciMedica, Inc. Common Stock (CALC)vsMerck & Company Inc (MRK)
CALC
CalciMedica, Inc. Common Stock
$0.62
+3.47%
HEALTHCARE · Cap: $9.22M
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 53/100 (C-).
CALC
Avoid19
out of 100
Grade: F
MRK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CALC.
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
The strongest argument for CALC centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CALC carries more volatility with a beta of 1.03 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (53/100 vs 19/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies targeting calcium-dependent pathways for the treatment of acute and chronic conditions. Its lead candidate, CM4620, is designed to alleviate severe muscle cramps associated with sickle cell disease, highlighting the company’s commitment to addressing critical unmet medical needs. CalciMedica leverages a proprietary technology platform to create innovative calcium modulators and has a robust pipeline supported by an experienced management team and strategic partnerships aimed at accelerating clinical development. With a focus on transforming treatment landscapes, CalciMedica presents a distinctive investment opportunity in the biopharmaceutical sector.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?